Chance of Survival 0.1%
Por um escritor misterioso
Descrição
Efficacy of Resectable NSCLC – TAGRISSO® (osimertinib) Nurse Center
Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®) - PDQ
Development of a Clinical Decision Support System for Severity
Status of minimal residual disease determines outcome of
Avian Reproduction: Post-hatching Parental Care and Brood
Multiparameter prediction of myeloid neoplasia risk
Future Internet, Free Full-Text
Robust Fit of Toxicokinetic–Toxicodynamic Models Using Prior
Minimal Residual Disease Testing in Acute Lymphoblastic Leukemia
de
por adulto (o preço varia de acordo com o tamanho do grupo)
